In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0815 GMT – Sanofi’s higher costs overshadow an upgrade to its ...

Mounjaro – which competes in the market with Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) – was 8% better than ...

A YOUNG woman has revealed that in 14 weeks, she has lost three stone on Mounjaro. But although Jess now feels “healthier” ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

RELATED: Ozempic and Mounjaro Patients Report Potentially Fatal New Side Effect. In speaking with The Cut, Jodi LoGerfo, DNP, a nurse practitioner and hair-loss specialist, points to telogen effluvium ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Danish leader will face a challenging landscape among competitors ...

Ozempic users are reporting unexpected hair loss, potentially linked to rapid weight loss and nutrient deficiencies, raising questions about the broader side effects of semaglutide medications.

Aggressive social media marketing by influencers has fuelled a surge in over-the-counter use of the diabetes and obesity ...

Wegovy, the blockbuster weight-loss drug, is now available in Singapore more than two years after it was approved by the ...